Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET

Core Viewpoint - Soleno Therapeutics, Inc. will report its first quarter 2025 financial results and operational highlights on May 7, 2025, followed by a conference call to discuss the results and business operations [1]. Group 1: Financial and Operational Updates - The financial results and operational highlights will be announced after the close of U.S. financial markets on May 7, 2025 [1]. - A conference call and webcast will take place at 4:30 PM Eastern Time on the same day to discuss the results [1][2]. Group 2: Product Information - Soleno's primary product, VYKAT XR, is indicated for treating hyperphagia in adults and pediatric patients aged 4 years and older with Prader-Willi syndrome [3][9]. - VYKAT XR is a once-daily oral treatment, previously known as DCCR [9]. Group 3: Safety Information - VYKAT XR has contraindications for patients with known hypersensitivity to diazoxide or thiazides [4]. - Warnings include the risk of hyperglycemia and fluid overload, necessitating regular monitoring of fasting plasma glucose and signs of edema [5][6]. - Common adverse reactions reported include hypertrichosis, edema, hyperglycemia, and rash [7].